Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Sawai Pharmaceutical To Sell 20 Percent Stake In U.S. Subsidiary To Sumitomo Corp.

By Upsher-Smith Laboratories, LLC | November 14, 2017

Upsher-Smith’s parent company forms strategic alliance with Sumitomo Corporation in U.S. generics market.

Upsher-Smith Laboratories, LLC‘s parent company, Japan-based Sawai Pharmaceutical Co., Ltd., will sell a 20 percent stake in its U.S. subsidiary (Sawai America Inc.*) to Sumitomo Corporation of Americas (SCOA), a subsidiary of Sumitomo Corporation, one of Japan’s general trading houses. Under the terms of the agreement, SCOA will acquire the stake for consideration of $211 million. The transaction is expected to close by the end of March 2018.   

Sumitomo Corporation’s core business units include tubular products, environment and infrastructure, steel and non-ferrous metals, transportation and construction systems, chemicals and electronics, media and IoT applications, real estate, mineral resources and Eenergy, and food.

“Sumitomo’s investment in our U.S. subsidiary and its management participation in Upsher-Smith will allow us to benefit from its experience, knowledge, and network in the global business arena in areas such as sourcing of active pharmaceutical ingredients (APIs) and product introduction,” said Mitsuo Sawai, president of Sawai. “By leveraging the unique strengths of the three companies, namely Sawai, Upsher-Smith, and Sumitomo Corporation, we will continue to enhance our global presence, including the U.S. business, to accelerate growth with the goal of becoming ‘a globally recognized generics company’.”

(Source: Upsher-Smith Laboratories, LLC)

Related Articles Read More >

Building a resilient pharma supply chain
Antheia_Logo (1)
Pharma ingredient manufacturer Antheia raises $56M Series C
These are the logos of Otsuka Medical and ICU Medical.
ICU Medical, Otsuka Pharmaceutical Factory launch joint IV supply chain venture
Amgen
Amgen to spend $900M to expand U.S. biopharma manufacturing
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE